The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli

Cellular Microbiology

Volumn 12, Issue 1, 2010, Pages 31-41

  Thanabalasuriar, Ajitha ^a,b   Koutsouris, Athanasia ^c   Weflen, Andrew ^c   Mimee, Mark ^a,b   Hecht, Gail ^c   Gruenheid, Samantha ^a,b  

^a Department of Microbiology and Immunology ^*  (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CELL PROTEIN; PROTEIN NLEA; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BREFELDIN A; CARRIER PROTEIN; ESCHERICHIA COLI PROTEIN; ESPFU PROTEIN, E COLI; MAP PROTEIN, E COLI; NLEA PROTEIN, E COLI;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL DISRUPTION; CELL MIGRATION; CONTROLLED STUDY; ENTEROPATHOGENIC ESCHERICHIA COLI; HELA CELL; HOST CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TRANSPORT; SMALL INTESTINE; TIGHT JUNCTION; CELL STRAIN CACO 2; DRUG EFFECT; ENDOPLASMIC RETICULUM; FLUORESCENCE MICROSCOPY; GENETIC COMPLEMENTATION; GENETICS; GOLGI COMPLEX; INTESTINE; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; TUMOR CELL LINE; TWO HYBRID SYSTEM; VIRULENCE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

BREFELDIN A; CACO-2 CELLS; CARRIER PROTEINS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; ENTEROPATHOGENIC ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENETIC COMPLEMENTATION TEST; GOLGI APPARATUS; HELA CELLS; HUMANS; INTESTINES; MICROSCOPY, FLUORESCENCE; TIGHT JUNCTIONS; TWO-HYBRID SYSTEM TECHNIQUES; VIRULENCE; VIRULENCE FACTORS;

EID: 77649211841     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/j.1462-5822.2009.01376.x     Document Type: Article

References (26)

1. Alto NM, Weflen AW, Rardin MJ, Yarar D, Lazar CS, Tonikian R. The type III effector EspF coordinates membrane trafficking by the spatiotemporal activation of two eukaryotic signaling pathways. J Cell Biol 2007, 178:1265-1278.
2. Canil C, Rosenshine I, Ruschkowski S, Donnenberg MS, Kaper JB, Finlay BB. Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect Immun 1993, 61:2755-2762.
3. Coombes BK, Wickham ME, Mascarenhas M, Gruenheid S, Finlay BB, Karmali MA. Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains. Appl Environ Microbiol 2008, 74:2153-2160.
4. Dean P, Kenny B. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol Microbiol 2004, 54:665-675.
5. Deborah Chen H, Frankel G. Enteropathogenic Escherichia coli: unravelling pathogenesis. FEMS Microbiol Rev 2005, 29:83-98.
6. Deng W, Puente JL, Gruenheid S, Li Y, Vallance BA, Vazquez A. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci USA 2004, 101:3597-3602.
7. Gauthier A, Puente JL, Finlay BB. Secretin of the enteropathogenic Escherichia coli type III secretion system requires components of the type III apparatus for assembly and localization. Infect Immun 2003, 71:3310-3319.
8. Gruenheid S, Finlay BB. Microbial pathogenesis and cytoskeletal function. Nature 2003, 422:775-781.
9. Gruenheid S, Sekirov I, Thomas NA, Deng W, O'Donnell P, Goode D. Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol 2004, 51:1233-1249.
10. Kenny B, Ellis S, Leard AD, Warawa J, Mellor H, Jepson MA. Co-ordinate regulation of distinct host cell signalling pathways by multifunctional enteropathogenic Escherichia coli effector molecules. Mol Microbiol 2002, 44:1095-1107.
11. Kim J, Thanabalasuriar A, Chaworth-Musters T, Fromme JC, Frey EA, Lario PI. The bacterial virulence factor NleA inhibits cellular protein secretion by disrupting mammalian COPII function. Cell Host Microbe 2007, 2:160-171.
12. Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR, Sotman S. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet 1978, 1:1119-1122.
13. McNamara BP, Donnenberg MS. A novel proline-rich protein, EspF, is secreted from enteropathogenic Escherichia coli via the type III export pathway. FEMS Microbiol Lett 1998, 166:71-78.
14. McNamara BP, Koutsouris A, O'Connell CB, Nougayrede JP, Donnenberg MS, Hecht G. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J Clin Invest 2001, 107:621-629.
15. Marches O, Batchelor M, Shaw RK, Patel A, Cummings N, Nagai T. EspF of enteropathogenic Escherichia coli binds sorting nexin 9. J Bacteriol 2006, 188:3110-3115.
16. Matsuzawa T, Kuwae A, Abe A. Enteropathogenic Escherichia coli type III effectors EspG and EspG2 alter epithelial paracellular permeability. Infect Immun 2005, 73:6283-6289.
17. Mundy R, Jenkins C, Yu J, Smith H, Frankel G. Distribution of espI among clinical enterohaemorrhagic and enteropathogenic Escherichia coli isolates. J Med Microbiol 2004a, 53:1145-1149.
18. Mundy R, Petrovska L, Smollett K, Simpson N, Wilson RK, Yu J. Identification of a novel Citrobacter rodentium type III secreted protein, EspI, and roles of this and other secreted proteins in infection. Infect Immun 2004b, 72:2288-2302.
19. Muza-Moons MM, Koutsouris A, Hecht G. Disruption of cell polarity by enteropathogenic Escherichia coli enables basolateral membrane proteins to migrate apically and to potentiate physiological consequences. Infect Immun 2003, 71:7069-7078.
20. Philpott DJ, McKay DM, Sherman PM, Perdue MH. Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol 1996, 270:G634-G645.
21. Simonovic I, Rosenberg J, Koutsouris A, Hecht G. Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions. Cell Microbiol 2000, 2:305-315.
22. Simonovic I, Arpin M, Koutsouris A, Falk-Krzesinski HJ, Hecht G. Enteropathogenic Escherichia coli activates ezrin, which participates in disruption of tight junction barrier function. Infect Immun 2001, 69:5679-5688.
23. Spitz J, Yuhan R, Koutsouris A, Blatt C, Alverdy J, Hecht G. Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. Am J Physiol 1995, 268:G374-G379.
24. Tomson FL, Viswanathan VK, Kanack KJ, Kanteti RP, Straub KV, Menet M. Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier. Mol Microbiol 2005, 56:447-464.
25. Wickham ME, Brown NF, Boyle EC, Coombes BK, Finlay BB. Virulence is positively selected by transmission success between mammalian hosts. Curr Biol 2007, 17:783-788.
26. Yuhan R, Koutsouris A, Savkovic SD, Hecht G. Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology 1997, 113:1873-1882.